Taking care of yourself whether that includes medication for diabetes, weight management, or other health issues ultimately benefits your whole family
While research is still emerging and clinical guidelines arent yet standardized, its widespread benefits in tissue repair, immune regulation, and inflammation control make it a promising candidate for integrative treatment plans aimed at BPC-157 healing chronic Lyme
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
DOI: 10.4093/dmj.2025.0106
